Nektar Therapeutics's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Nektar Therapeutics's ROA in the second quarter of 2026?
Nektar Therapeutics recorded a cumulative net loss of $-157 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -25.81%.

However, within the Healthcare sector 391 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3800, from total ROA ranking in the first quarter of 2026 at 4727.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	442.34 %	205.19 %	-5.45 %	-1.53 %	-39.68 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-157	-158	-164	-121	-122
Return On Assets (TTM)	-25.81 %	-41.02 %	-63.82 %	-46.23 %	-46.61 %
NKTR's Total Ranking	# 3800	# 4727	# 3976	# 4028	# 4068
Total Assets (TTM) in million	1,095	763	280	296	202
Seq. Total Assets Change	43.48 %	172.2 %	-5.27 %	46.6 %	-19.26 %
Seq. Net Income Change	-	-	-	-	-

NKTR's 5 Years Annual ROA >> Back to NKTR Management Effectiveness >> Compare NKTR ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 147
Sector	# 392
Overall	# 3527

Return On Assets Statistics
High	Average	Low
92.57 %	-26.49 %	-62.77 %
(Jun 30 2018)		(Dec 31 2025)

Financial Statements
Nektar Therapeutics's Assets	$ 1,095 million	NKTR's Balance sheet
Nektar Therapeutics's Income	$ -41 million	Quarterly NKTR's Income Statement
NKTR's Income by Division		See NKTR's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-4.27 %	-22.44 %	-41.97 %	-34.27 %	-58.76 %
Total Assets in million	284	297	382	659	1,002
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-164	-119	-276	-368	-524
Annual Return On Assets	-57.79 %	-40.11 %	-72.19 %	-55.88 %	-52.26 %

NKTR's 5 Years Annual ROA >> Back to NKTR Management Effectiveness >> Compare NKTR ROA to its Competitors

More Return On Assets Ratios
NKTR's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
NKTR's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for NKTR's Competitors
Subscribers only: Roa for Nektar Therapeutics's Suppliers
Subscribers only: Return On Assets for NKTR's Customers

You may also want to know
NKTR's Roi	NKTR's Inventory Turnover Ratio	NKTR's Growth Rates	NKTR's Dividend Comparisons
	NKTR's Profitability Ratios	NKTR's Asset Turnover Ratio	NKTR's Dividend Growth
NKTR's Roe	NKTR's Valuation Ratios	NKTR's Financial Strength Ratios	NKTR's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:10:40+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.